Premium
Intermittent melphalan in the treatment of essential thrombocytosis with haemorrhage or thrombosis
Author(s) -
Pauw B. E.,
Bergen A. N. L.,
Haanen C.,
Steenbergen J.
Publication year - 1985
Publication title -
scandinavian journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0036-553X
DOI - 10.1111/j.1600-0609.1985.tb02270.x
Subject(s) - thrombocytosis , melphalan , medicine , platelet , thrombosis , refractory (planetary science) , surgery , gastroenterology , chemotherapy , physics , astrobiology
178 episodes of essential thrombocytosis with symptoms of haemorrhage or thrombosis, were treated in 15 patients with melphalan (5 mg/m 2 orally during 4 d). An average reduction in the platelet count of 77% was achieved by oral melphalan in 14 responding patients. 1 patient appeared to be refractory to oral therapy, but a decrease of the thrombocyte count was achieved after intravenous administration of melphalan. All responding patients experienced a relief of the thrombocytosis‐associated clinical symptoms. Reduction of the thrombocyte count persisted for 3–4 wk.